Abilify gains US approval for adjunctive maintenance use in bipolar disorder
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical/Bristol-Myers Squibb's atypical antipsychotic Abilify (aripiprazole) has been approved in the US for the maintenance treatment of bipolar I disorder in conjunction with either lithium or valproate therapy.